1-3 of 3
Mark Bray
Close
Sort by
Journal Articles

A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia

Karen W.L. Yee, MD, Hsaio-Wei Tina Chen, Joseph Brandwein, MD, FRCPC, Sue Chow, Deborah Sanfelice, David Hedley, MD, Vikas Gupta, MD, MRCP, FRCPath, Aaron Schimmer, MD, PhD, Carolyn Fowler Sidor, MD, Graham Fletcher, Jamie Arnott, Mark Bray, Mark D. Minden, MD, PhD, Andre Schuh, MD, FRCPC
Journal: Blood
Blood (2010) 116 (21): 3307.
https://doi.org/10.1182/blood.V116.21.3307.3307
Published: 2010
Journal Articles

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results

Sherif Farag, MD, PhD, Shuhong Zhang, PhD, Attaya Suvannasankha, MD, Jing Liang, MD, Robyn O'Bryant, RN, Wood Lisa, RN, Sushil Gupta, PhD, Mark Bray, PhD, Carolyn Fowler Sidor, MD, Rafat Abonour, MD
Journal: Blood
Blood (2010) 116 (21): 1957.
https://doi.org/10.1182/blood.V116.21.1957.1957
Published: 2010
Journal Articles

A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy

Qiang Jeremy Wen, MD, PhD, Serena Silver, PhD, Tim Lewis, PhD, Sridevi Ponduru, MBBS, PhD, Vlado Dancik, phd, Ben Goldenson, Mark Bray, Anne Carpenter, PhD, Paul Clemons, PhD, David Root, phd, Andrew Stern, phd, Robert Gould, phd, John Crispino, PhD
Journal: Blood
Blood (2010) 116 (21): 89.
https://doi.org/10.1182/blood.V116.21.89.89
Published: 2010